Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Updates in Surgery
Published in: Updates in Surgery 6/2022

18-09-2022 | Vomiting | Review Article

The short- and long-term survival of hyperthermic intraperitoneal chemotherapy (HIPEC) in the advanced gastric cancer with/without peritoneal carcinomatosis: a systematic review and meta-analysis of randomized controlled trials

Authors: Huachu Deng, Baibei Li, Xingan Qin

Published in: Updates in Surgery | Issue 6/2022

Login to get access

Abstract

To evaluate the short- and long-term survival of hyperthermic intraperitoneal chemotherapy (HIPEC) in the patients with advanced gastric cancer (AGC) through randomized controlled trials (RCTs). We analyzed the endpoints of AGC patients including 1-, 2-, 3-, and 5-year overall survival (OS), intestinal anastomotic leakage, myelosuppression, nausea and vomiting from included studies. And we retrieved RCTs from medical literature databases. Risk ratios (RR) was used to calculated the endpoints. Totally, we retrieved 13 articles (14 trial comparisons) which contained 1091 patients. They were randomized to HIPEC group and control group. The results showed that there was no significant differences in survival rates between HIPEC group and control group at 1-, 2- and 3-year follow-up, while a statistical significant overall survival effect was found at the 5-year follow-up [RR: 1.20, 95% CI 1.01 to 1.43, I2 = 0.0%]. And there is no significant difference in the risk of intestinal anastomotic leakage, myelosuppression and nausea and vomiting. Compared with the control group, HIPEC could improve the long-term OS without increasing the risk of adverse effect in AGC patients with/without peritoneal carcinomatosis, but there was no benefit at short-term OS.
Appendix
Available only for authorised users
Literature
1.
Correa P (2013) Gastric cancer: overview. Gastroenterol Clin N Am 42:211–217CrossRef
2.
Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin 71(3):209–249
3.
Chen WQ, Li H, Sun KX et al (2018) Report of cancer incidence and mortality in China, 2014 Zhonghua zhong liu za zhi. Chin J Oncol 40(1):5–13
4.
Fujitani K (2013) Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East. Dig Surg 30(2):119–129CrossRefPubMed
5.
Yarema R, Mielko J, Fetsych T et al (2019) Hyperthermic intraperitoneal chemotherapy (HIPEC) in combined treatment of locally advanced and intraperitoneally disseminated gastric cancer: a retrospective cooperative central-Eastern European study. Cancer Med 45:144CrossRef
6.
Zheng GZ, Rui T, Min Y et al (2006) Efficacy and safety of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer patients with serosal invasion. A long-term follow-up study Dig Surg 23(1–2):93–102
7.
Spratt JS, Adcock RA, Muskovin M et al (1980) Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Can Res 40(2):256–260
8.
Mar A, Jpm B, Rb C et al (2020) A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 244:101–105CrossRef
9.
Klaver C, Wisselink DD, Punt C et al (2019) Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol 4(10):761–770CrossRefPubMed
10.
Cortés-Guiral D, Mohamed F, Glehen O et al (2020) "Prehabilitation of patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. Eur J Surg Oncol 47(1):60–64CrossRefPubMed
11.
Dahdaleh FS, Turaga KK (2018) Evolving treatment strategies and outcomes in advanced gastric cancer with peritoneal metastasis. Surg Oncol Clin N Am 27(3):519–537CrossRefPubMed
12.
Beeharry MK, Zhu ZL, Liu WT et al (2019) Correction to: Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study. BMC Cancer 19(1):1–3
13.
Golse N, Bakrin N, Passot G et al (2012) Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results. J Surg Oncol 106(2):197–203CrossRefPubMed
14.
Sugarbaker PH (2016) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: progress toward a new standard of care. Cancer Treat Rev 48:42–49CrossRefPubMed
15.
Page MJ, Mckenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 10(1):1–11CrossRef
16.
Higgins JPT, Altman DG, Gtzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928
17.
Koga S, Hamazoe R, Maeta M et al (1988) Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 61:232–237CrossRefPubMed
18.
Kaibara N, Hamazoe R, Iitsuka Y et al (1989) Hyperthermic peritoneal perfusion combined with anticancer chemotherapy as prophylactic treatment of peritoneal recurrence of gastric cancer. Hepatogastroenterology 36(2):75–78PubMed
19.
Hamazoe R, Maeta M, Kaibara N (2015) Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 73(8):2048–2052CrossRef
20.
Fujimura T, Yonemura Y, Muraoka K et al (1994) Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg 18(1):150CrossRefPubMed
21.
Ikeguchi M, Kondou A, Oka A et al (1995) Effect of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur J Surg 161(8):581–586PubMed
22.
Fujimoto S, Takahashi M, Mutou T et al (2015) Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 85(3):529–534CrossRef
23.
Yonemura Y, Aretxabala XD, Fujimura T et al (2001) Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterology 48(42):1776–1782PubMed
24.
Yang XJ, Huang CQ, Suo T et al (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 18(6):1575–1581CrossRefPubMedPubMedCentral
25.
Cui H, Ge H, Bai X et al (2014) Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer. Exp Ther Med 7(5):1083–1088CrossRefPubMedPubMedCentral
26.
Huang O, Lu XH, Xu XD et al (2015) Fibrin-sealant-delivered cisplatin chemotherapy versus cisplatin hyperthermic intraperitoneal perfusion chemotherapy for locally advanced gastric cancer without peritoneal metastases: a randomized phase-ii clinical trial with a 40-month follow-up. Cell Biochem Biophys 71(2):1171–1180CrossRefPubMed
27.
Rudloff U, Langan RC, Mullinax JE et al (2014) Impact of maximal cytoreductive surgery plus regional heated intra-peritoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol 110(3):275–284CrossRefPubMedPubMedCentral
28.
Lu C, Li L, Luo Z et al (2016) Clinical efficacy of type-B ultrasound-guided intraperitoneal hyperthermic chemoperfusion combined with systemic chemotherapy in advanced gastric cancer patients with malignant ascites. Neoplasma 63:299–303PubMed
29.
Fan B, Bu Z, Zhang J et al (2021) Phase II trial of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery. BMC Cancer 21(1):216CrossRefPubMedPubMedCentral
30.
Sterne J, Savovi J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ Clin Res 366:l4898
31.
Afsar B, Kanbay M (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(14):1362CrossRefPubMed
32.
Nissan A, Garofalo A, Esquivel J (2010) Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for gastric adenocarcinoma: why haven’t we reached the promised land? J Surg Oncol 102(5):359–360CrossRefPubMed
33.
Reutovich MY, Krasko OV, Sukonko OG (2021) Hyperthermic intraperitoneal chemotherapy in prevention of gastric cancer metachronous peritoneal metastases: a systematic review. J Gastrointest Oncol 12(Suppl 1):S5–S17CrossRefPubMedPubMedCentral
34.
Ji Z, Zhang Y, Li Y (2021) Intra-operative hyperthermic intraperitoneal chemotherapy for prevention and treatment of peritoneal metastases from gastric cancer: a narrative review. J Gastrointest Oncol 12(1):S70–S78CrossRefPubMedPubMedCentral
35.
Pallas N, Karamveri C, Kyziridis D et al (2017) Cytoreductive surgery and hyperthermic intraperitenoal chemotherapy (HIPEC) for colorectal and appendiceal carcinomas with peritoneal carcinomatosis. J BUON: Off J Balk Union Oncol 22(6):1547–1553
36.
Di N, Liu F et al (2009) Destruction of gastric cancer cells to mesothelial cells by apoptosis in the early peritoneal metastasis. J Huazhong Univ Sci Technol Med Sci 29:163–168CrossRef
37.
Liu G, Huang JP (2011) The clinical analysis of laparoscopic assisted D_2 radical gastrectomy for progressed gastric carcinoma. Chin J Mod Op Surg 15(5):355-357
38.
Desiderio J, Chao J, Melstrom L et al (2017) The thirty-year experience - a meta-analysis of randomized and high-quality non-randomized studies of hyperthermic intraperitoneal chemotherapy(HIPEC) in the treatment of gastric cancer. Eur J Cancer 79:1–14CrossRefPubMedPubMedCentral
39.
Liu Y-W, Ying Du et al (2019) Effect of hyperthermic intraperitoneal chemotherapy for gastric cancer patients: a meta-analysis of the randomized controlled trials. J Int Med Res 47(12):5926–5936CrossRefPubMedPubMedCentral
Metadata
Title
The short- and long-term survival of hyperthermic intraperitoneal chemotherapy (HIPEC) in the advanced gastric cancer with/without peritoneal carcinomatosis: a systematic review and meta-analysis of randomized controlled trials
Authors
Huachu Deng
Baibei Li
Xingan Qin
Publication date
18-09-2022
Publisher
Springer International Publishing
Published in
Updates in Surgery / Issue 6/2022
Print ISSN: 2038-131X
Electronic ISSN: 2038-3312
DOI
https://doi.org/10.1007/s13304-022-01376-5

Other articles of this Issue 6/2022

Updates in Surgery 6/2022 Go to the issue

Original Article

Surgery for mesenchymal neoplasms of the esophagus: experience over 2 decades from a tertiary healthcare center in India

Original Article

Kingsnorth's modified score as predictor of complications in open inguinal hernia repair

Original Article

Tumor size predicts worse prognosis in esophagogastric junction adenocarcinoma

Original Article

Tension-free thyroidectomy (TFT): initial report

Original Article

All elderly are fragile, but some are more fragile than others: an epidemiological study from one of the busiest trauma centers in Italy

Original Article

Impact of AirSeal® insufflation system on respiratory and circulatory dynamics during laparoscopic abdominal surgery